ICODE: the international COVID-19 thrombosis biomarkers colloquium—novel soluble biomarkers: circulating cell-free nucleic acids and other molecules

Krauel, Krystin; Duerschmied, Daniel

doi:10.1007/s11239-021-02468-6

Cited by 5 publications

(2 citation statements)

References 31 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The complement protein C3 was also found to be elevated in COVpos patients in comparison to healthy controls in a previous study [42,43], as was sC5b-9 [9,44,45]. The levels of complement C5 and C5a were also shown to be elevated in comparison to healthy controls [22,42,43,45]. Our results do not, however, provide evidence that increased levels of C3, C5, and C5a characterize by COVID-19 in contrast to other pulmonary infections.…”

Section: Higher Complement Markers Are Associated With Disease Severi...contrasting

confidence: 82%

See 1 more Smart Citation

The Role of NETosis and Complement Activation in COVID-19-Associated Coagulopathies

et al. 2023

View full text Add to dashboard Cite

Inflammation-induced coagulopathy is a common complication associated with coronavirus disease 2019 (COVID-19). We aim to evaluate the association of NETosis and complement markers with each other as well as their association with thrombogenicity and disease severity in COVID-19. The study included hospitalized patients with an acute respiratory infection: patients with SARS-CoV2 infection (COVpos, n = 47) or either pneumonia or infection-triggered acute exacerbated COPD (COVneg, n = 36). Our results show that NETosis, coagulation, and platelets, as well as complement markers, were significantly increased in COVpos patients, especially in severely ill COVpos patients. NETosis marker MPO/DNA complexes correlated with coagulation, platelet, and complement markers only in COVpos. Severely ill COVpos patients showed an association between complement C3 and SOFA (R = 0.48; p ≤ 0.028), C5 and SOFA (R = 0.46; p ≤ 0.038), and C5b-9 and SOFA (R = 0.44; p ≤ 0.046). This study provides further evidence that NETosis and the complement system are key players in COVID-19 inflammation and clinical severity. Unlike previous studies that found NETosis and complement markers to be elevated in COVID-19 patients compared to healthy controls, our findings show that this characteristic distinguishes COVID-19 from other pulmonary infectious diseases. Based on our results, we propose that COVID-19 patients at high risk for immunothrombosis could be identified via elevated complement markers such as C5.

show abstract

Section: Higher Complement Markers Are Associated With Disease Severi...contrasting

confidence: 82%

Section: Higher Complement Markers Are Associated With Disease Severi...mentioning

confidence: 58%

The Role of NETosis and Complement Activation in COVID-19-Associated Coagulopathies

et al. 2023

View full text Add to dashboard Cite

show abstract

Cell free DNA as a new prognostic biomarker for COVID-19, A prospective cohort study

Erdem,

Balkan,

Karaali

et al. 2024

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes

Matacchione

Giuliani

Ramini

et al. 2022

Mechanisms of Ageing and Development

View full text Add to dashboard Cite

ICODE: the international COVID-19 thrombosis biomarkers colloquium—novel soluble biomarkers: circulating cell-free nucleic acids and other molecules

Cited by 5 publications

References 31 publications

The Role of NETosis and Complement Activation in COVID-19-Associated Coagulopathies

The Role of NETosis and Complement Activation in COVID-19-Associated Coagulopathies

Cell free DNA as a new prognostic biomarker for COVID-19, A prospective cohort study

Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes

Contact Info

Product

Resources

About